Back to Agenda
Big Data: Impact on Innovation
Session Chair(s)
Susan Dentzer, MA
Senior Policy Fellow
Duke Margolis Center for Health Policy, United States
With the greater use of electronic data, access to real-world data on patients, payers and the health system is exploding, bringing with it many opportunities to shape drug development, commercialization and access. Many significant initiatives with broad impact have been undertaken to shape how these types of data are being used to guide decision-making. How are these data being used to support safety and effectiveness? Does this information impact the payer landscape? What are the gaps and limitations? What are the standards, if any, available to guide good practice?
A short keynote address will set the groundwork and will be followed by a panel discussion that will examine pharma, safety, and patient perspectives on big data methodology and the need for real-world examples.
Learning Objective : Discuss how the data are being used to support safety and effectiveness; Explain how the payer landscape is impacted by using big data; Discuss early strategies for establishing standards for guiding good practice.
Speaker(s)
Keynote
Michael Rosenblatt, MD
Flagship Pioneering, United States
Chief Medical Officer
Panelist
Marc M. Boutin, JD
Novartis , Switzerland
Global Head of Patient Engagement and Advocacy
Panelist
David W. Bates, MD, MSc
Brigham and Women's Hospital, United States
Chief, Division of General Internal Medicine and Primary Care
Panelist
Rachael Fleurence, PhD
Patient-Centered Outcomes Research Institute (PCORI), United States
Program Director, CER Methods and Infrastructure
Have an account?